Past research studies
The following studies are no longer recruiting participants. To find our more about the results of these studies contact the researchers directly.
INC Research/inVentiv Health Australia - A Clinical Study for Non-Radiographic Axial Spondyloarthritis (nr-ax SpA)
Nr-ax SpA is a type of arthritis usually diagnosed in early adulthood that involves pain and stiffness in the lower back, hip joints, and buttocks during the waking hours and after periods of inactivity. Treatments may decrease pain and lessen symptoms.
If your nr-ax SpA symptoms persist despite current treatments, you may want to consider participating in a clinical research study with an investigational study medication.
You may be eligible to participate in this clinical study if you:
- Are 18 to 49 years of age;
- Currently take an anti-inflammatory drug for nr-ax SpA and continue to have back pain;
- Have had nr-ax SpA symptoms for at least 3 months or less than 5 years;
- Are willing to follow a study treatment plan, routinely scheduled study visits, and other study tests and procedures over an 21-month period.
Qualified participants will receive study-related medical care and investigational study medication at no cost while enrolled in the study.
Three study sites in Australia are currently looking for people to participate in this clinical study. For more information about this study, please contact:
Maroochydore, Qld – Rheumatology Research Unit, Coast Joint Care
Ms. Dale Shergold | Email: firstname.lastname@example.org | Ph: 07 5443 1033
Newcastle, NSW – Genesis Research Services
Dominic Bailey | Email: email@example.com | Ph: 02 4985 1860
Perth, WA – R.K Will Pty Ltd, Colin Bayliss Teaching and Research Unit
Julie Uhlmann or Agatha Khow | Email: Juhlmann@bdaus.com.au | Ph: 08 9472 1904 (option 3)
University of Tasmania - Do you use prescription-only opioid medications to manage chronic pain?
Researchers at the University of Tasmania are conducting a brief online survey about the experiences of people who use prescription-only opioid medications to manage chronic non-cancer pain. Participants will be asked about medication use, pain, cognitive functioning, and physical and mental health.
- male or female participants aged 18 – 65 years
- currently using prescription opioids as treatment for chronic pain (lasting three months or more) that is not related to cancer.
Participants can enter the draw to win one of five $50 vouchers.
Access the survey click here
For more information contact Jane Akhurst: firstname.lastname@example.org
CMAX Study - Do you have Osteoarthritis of the hip or knee?
CMAX is an independent, clinical trial facility located at 18a North Terrace in Adelaide, that carries out research on a variety of investigational medicines for the pharmaceutical industry.
CMAX is conducting a study of an investigational medication for the treatment of pain associated with osteoarthritis of the hip or knee.
This trial has been approved by the Bellberry Human Research Ethics Committee.
We are seeking volunteers aged over 18 years that have osteoarthritis of the hip or knee. The trial involves 12 visits to the CMAX unit over a 21 month period.
For more information about the CMAX study click here.
If you are interested in participating, please phone CMAX on 1800 150 433.
Queensland University of Technology (QUT) trial - Testing of a program to reduce chronic pain and associated health outcomes
For adults with chronic pain in Brisbane: Participants needed for QUT trial of a 3-week computer-based program.
This project aims to investigate whether a new psychological program, completed on a computer once a week for 3 consecutive weeks, can reduce chronic pain and associated health outcomes. Participation will include completing 3 short computer-based sessions (10-20 min each, over 3 weeks at one of the QUT Brisbane campuses) and some online surveys.
To find out more and enter the initial survey click here.
For any questions, please email email@example.com.
Regulating Autologous Stem Cell Therapies in Australia
The University of Sydney is looking for participants for an Australian Research Council-funded research project exploring the regulation of autologous adult stem cell (ASC) therapies in Australia.
The study seeks to explore the attitudes of major stakeholders regarding patient access to innovative ASC therapies. Despite limited evidence of their efficacy and safety, ASCs (stem cells derived from the patient’s own body) are increasingly being offered for the treatment of a wide range of conditions, including chronic diseases, asthma, dementia, motor neurone disease or arthritis.
We are looking for health professionals, patient representatives and patients, their carers and family members to take part in a workshop (Nov 21 in Sydney and Nov 28 in Melbourne) and/or a short interview exploring their views on ASC therapies in Australia. Workshop participants will be offered $50 reimbursement for travel to and from the workshop and a $50 supermarket voucher. The study is confidential and anonymity is guaranteed to participants.
If you would like to participate, please contact Dr Tereza Hendl at firstname.lastname@example.org.
More information about the study can be found at: http://sydney.edu.au/law/health/stemcells/index.shtml
Testing the safety, tolerability and efficacy of a new medication called AKP-11 administered to participants with arthritis
You are invited to take part in this research project if you have been diagnosed with a form of arthritis and are aged between 18 years and 65 years. This research project is testing the safety, tolerability and efficacy (how well the drug works in alleviating pain) of a new medication called AKP-11, which will be administered to participants with arthritis.
AKP-11 is an experimental topical, anti-inflammatory drug for the treatment of arthritis, including gout. This drug is believed to curb a variety of the pathological events associated with arthritis via a multi-modal mechanism of action. The study seeks to determine the safety, tolerability, and efficacy of topical doses of AKP-11 compared to matching placebo in participants with rheumatoid arthritis or gout.
For further information visit www.anzctr.org.au/ and enter the identifier ACTRN 12616000922471 in the search box and click on the link provided.
Participate in an Australian-wide study on biologic use in pregnancy
- Do you have an inflammatory arthritis such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis?
- Are you a woman aged over 18?
- Are you on or have you been on an injection treatment for your arthritis?
- Have you had a pregnancy or are you currently pregnant?
Phone: 0452 423 970
Potential Treatment for Symptoms of Osteoarthritis in the Knee
A randomised clinical trial of a treatment for mild to moderate osteoarthritis of the knee.
The study is looking for participants aged between 40 and 80 years of age, with mild OA in either or both knees to test a treatment for 8 weeks.
Trial volunteers would need to:
- Make 3 visits to the clinic – week 1, week 4 and week 8
- Have blood tests at a QML collection centre – week 1, week 4 and week 8
- Take the medication daily for 8 weeks
Clinic locations are in Brisbane and Redcliffe and Sunshine Coast
For further information please contact:
Phone: (07) 3162 0909
Fast Vs slow weight loss - which is better? The TEMPO Diet Trial
Losing excess weight is scientifically proven to help reduce and prevent joint pain. One way to get support for weight loss is to participate in a clinical weight loss trial, where you get the support of a research team and others in the trial.
For many years health professionals have recommended ‘slow and steady’ weight losses of approximately 0.1 to 1 kilo per week. In recent years however, an increasing number of health professionals are prescribing meal replacement diets called very low calorie diets (VLCDs) because they can induce relatively fast weight losses of approximately 0.5 to 2 kilos per week, which some people find motivating, and because some people report not feeling hungry while following a VLCD.
While VLCDs are known to be safe and effective in the short-term (for up to one year), the long-term consequences are unknown. This study will demonstrate whether or not there is any difference between the effects of weight loss via VLCD or conventional diet on metabolic health, body fat content and distribution, muscle mass and strength, and bone density in post-menopausal women for 3 years after commencement of the diet.
- To watch Associate Professor Amanda Salis talking about the TEMPO Diet Trial click here.
- To watch Associate Professor Amanda Salis talking about A Day in the Life on a VLCD, click here.
- To read the Information for Participants click here (PDF file).
Recruitment for the TEMPO Diet Trial is currently underway. If you are interested in participating in this trial and are female, living in the Sydney metropolitan area, aged 45-65, postmenopausal for 5 years or more, are non-diabetic and you have a body mass index (BMI*) of 30 to 40 kg/m2, you may be eligible for this study.
*To calculate your BMI, divide your weight in kilograms by the square of your height in meters, or use this web-based BMI calculator: http://www.heartfoundation.org.au/healthy-eating/Pages/bmi-calculator.aspx.
For more information contact The TEMPO Team (Ms Michelle Hsu, Dr Radhika Seimon, Ms Alice Gibson and Associate Professor Amanda Salis) on email@example.com
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox: